Comments
Laurus Labs Limited has completed the US Food and Drug Administration (USFDA) inspection of its API facilities in Units 1 & 3 at Parawada, Visakhapatnam, Andhra Pradesh, with two observations.
In a press release issued here, the company said the observations ``are only procedural in nature.''
``This is a regular surveillance audit by USFDA, and no data integrity issues were observed in the inspection,'' it added.
Laurus Labs' scrip lost 1.87 per cent on the Bombay Stock Exchange on Monday to end at Rs 526.35.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.